Literature DB >> 1632401

Studies of Left Ventricular Dysfunction (SOLVD) Registry: rationale, design, methods and description of baseline characteristics.

S I Bangdiwala1, D H Weiner, M G Bourassa, G C Friesinger, J K Ghali, S Yusuf.   

Abstract

The Studies of Left Ventricular Dysfunction (SOLVD) comprises 2 double-blind, randomized clinical trials to test improved survival by angiotensin-converting enzyme inhibitor in patients with left ventricular dysfunction, with or without congestive heart failure. Patients entering the trials may be a highly selected subset of the population of such patients; those with the worst and best prognosis are likely to be excluded. To obtain the clinical history of a broader group, a registry of 6,273 patients included a relatively unselected cohort of patients with heart failure or left ventricular dysfunction, or both, from SOLVD hospitals. Registry data were obtained from hospital records. Because data collection from medical records may lead to incomplete data and more investigations in "sicker" patients, 898 randomly chosen subjects from different disease strata were seen in clinic where neurohumoral measures, echocardiograms, x-rays and electrocardiograms were obtained, and a 6-minute walking test was performed. The design and methodologic features, and the baseline characteristics of the participants in this 2-tiered registry are described, and its use in complementing the results and interpretation of the SOLVD trials is discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1632401     DOI: 10.1016/0002-9149(92)90617-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

1.  Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and design.

Authors:  James T Willerson; Emerson C Perin; Stephen G Ellis; Carl J Pepine; Timothy D Henry; David X M Zhao; Dejian Lai; Marc S Penn; Barry J Byrne; Guilherme Silva; Adrian Gee; Jay H Traverse; Antonis K Hatzopoulos; John R Forder; Daniel Martin; Marvin Kronenberg; Doris A Taylor; Christopher R Cogle; Sarah Baraniuk; Lynette Westbrook; Shelly L Sayre; Rachel W Vojvodic; David J Gordon; Sonia I Skarlatos; Lemuel A Moyé; Robert D Simari
Journal:  Am Heart J       Date:  2010-08       Impact factor: 4.749

Review 2.  Post-myocardial Infarction Heart Failure: A Review on Management of Drug Therapies.

Authors:  Gautam Swaroop
Journal:  Cureus       Date:  2022-06-08

3.  Adverse effects of ACE inhibitors in patients with chronic heart failure and/or ventricular dysfunction : meta-analysis of randomised clinical trials.

Authors:  Antònia Agustí; Sara Bonet; Josep Maria Arnau; Xavier Vidal; Joan-Ramon Laporte
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 4.  Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology.

Authors:  Nathaniel Mark Hawkins; Mark C Petrie; Pardeep S Jhund; George W Chalmers; Francis G Dunn; John J V McMurray
Journal:  Eur J Heart Fail       Date:  2009-02       Impact factor: 15.534

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.